Do biologics improve health outcomes in children with severe asthma? A cohort study

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

Extract Asthma is a common chronic lung disease in children, and those with severe asthma suffer from poor symptom control despite treatment plan adherence [1]. Severe asthma is a heterogenous disease associated with different inflammatory phenotypes, and the most common phenotype is characterised by increased T-helper 2 (Th-2) cytokines and mediators [1–3]. Release of these biomarkers leads to increased airflow obstruction, airway hyperresponsiveness, mucus production, and remodelling responses; leading to increased symptoms, exacerbations, school absenteeism and decreased quality of life [4, 5]. extract abstract-1 Shareable abstract Biologics may improve children's severe asthma, decreasing corticosteroid use, healthcare utilisation and serum eosinophils. Future research needs to explore the best timing for initiating and terminating biologics in children. https://bit.ly/3MtXdQM short abstract-2